Elizabeth O. Hexner

14.5k total citations
154 papers, 4.0k citations indexed

About

Elizabeth O. Hexner is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Elizabeth O. Hexner has authored 154 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Hematology, 46 papers in Oncology and 45 papers in Genetics. Recurrent topics in Elizabeth O. Hexner's work include Hematopoietic Stem Cell Transplantation (48 papers), Acute Myeloid Leukemia Research (41 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers). Elizabeth O. Hexner is often cited by papers focused on Hematopoietic Stem Cell Transplantation (48 papers), Acute Myeloid Leukemia Research (41 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers). Elizabeth O. Hexner collaborates with scholars based in United States, Germany and China. Elizabeth O. Hexner's co-authors include Stephen G. Emerson, Jiang Zhu, Gerard Joe, Yi Zhang, Noelle V. Frey, Selina M. Luger, Alison W. Loren, Saar Gill, Edward A. Stadtmauer and Carl H. June and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Elizabeth O. Hexner

146 papers receiving 4.0k citations

Peers

Elizabeth O. Hexner
Pearlie K. Epling‐Burnette United States
Luen Bik To Australia
Vincent Praloran France
Hyeoung‐Joon Kim South Korea
Simrit Parmar United States
Javier Pinilla‐Ibarz United States
Kazimierz Kuliczkowski Poland
David A. Sallman United States
George E. Georges United States
Anna Ritá Migliaccio Italy
Pearlie K. Epling‐Burnette United States
Elizabeth O. Hexner
Citations per year, relative to Elizabeth O. Hexner Elizabeth O. Hexner (= 1×) peers Pearlie K. Epling‐Burnette

Countries citing papers authored by Elizabeth O. Hexner

Since Specialization
Citations

This map shows the geographic impact of Elizabeth O. Hexner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth O. Hexner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth O. Hexner more than expected).

Fields of papers citing papers by Elizabeth O. Hexner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth O. Hexner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth O. Hexner. The network helps show where Elizabeth O. Hexner may publish in the future.

Co-authorship network of co-authors of Elizabeth O. Hexner

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth O. Hexner. A scholar is included among the top collaborators of Elizabeth O. Hexner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth O. Hexner. Elizabeth O. Hexner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gangat, Naseema, James M. Foran, Anna B. Halpern, et al.. (2024). A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia. Blood. 144(Supplement 1). 657–657. 3 indexed citations
3.
Gangat, Naseema, James M. Foran, Anna B. Halpern, et al.. (2024). A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Participants With Myelofibrosis and Anemia. Clinical Lymphoma Myeloma & Leukemia. 24. S201–S201. 1 indexed citations
4.
He, Shan, Tien D. Bui, Yuanyuan Tian, et al.. (2023). Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD. Blood. 143(2). 166–177. 6 indexed citations
5.
Logun, Meghan, Stephen Bagley, Daniel Zhang, et al.. (2023). CTIM-40. EARLY RADIOGRAPHIC RESPONSE AND ENGRAFTMENT OF PHASE I FIRST-IN-HUMAN BICISTRONIC CAR T CELLS CORRELATE WITH REAL-TIME AUTOLOGOUS GBM ORGANOID CYTOLYSIS. Neuro-Oncology. 25(Supplement_5). v72–v72. 1 indexed citations
6.
Ren, Jian‐Gang, Bowen Xing, Kaosheng Lv, et al.. (2023). RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia. Journal of Clinical Investigation. 133(12). 24 indexed citations
7.
8.
Matthews, Andrew, Alexander E. Perl, Selina M. Luger, et al.. (2022). Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Advances. 6(13). 3997–4005. 53 indexed citations
9.
Loren, Alison W., Elizabeth O. Hexner, Mary Ellen Martin, et al.. (2022). Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies. Transplantation and Cellular Therapy. 29(2). 113–118. 2 indexed citations
10.
Vasu, Sumithira, Nelli Bejanyan, Steven M. Devine, et al.. (2021). BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). Transplantation and Cellular Therapy. 27(3). S430–S431. 2 indexed citations
11.
DeAngelo, Daniel J., Deepti Radia, Tracy I. George, et al.. (2021). Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature Medicine. 27(12). 2183–2191. 88 indexed citations
12.
Tian, Yuanyuan, Lijun Meng, Ying Wang, et al.. (2020). Graft-versus-host disease depletes plasmacytoid dendritic cell progenitors to impair tolerance induction. Journal of Clinical Investigation. 131(1). 23 indexed citations
13.
14.
Tian, Yuanyuan, Lijun Meng, Elizabeth O. Hexner, et al.. (2018). Graft-Versus-Host Disease Impairs the Histone Methyltransferase Dot1l-Regulated Reconstitution of Plasmacytoid Dendritic Cells in Mice Undergoing Allo-HSCT. Blood. 132(Supplement 1). 477–477. 1 indexed citations
15.
Cummins, Katherine D., Noelle V. Frey, Anne Marie Nelson, et al.. (2017). Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells. Blood. 130. 1359–1359. 92 indexed citations
16.
Reiter, Alfred, Hanneke C. Kluin‐Nelemans, Cem Akin, et al.. (2017). Pooled Survival Analysis Of Midostaurin Clinical Study Data (D2201+A2213) In Patients With Advanced Systemic Mastocytosis Compared With Historical Controls. Haematologica. 7 indexed citations
17.
Kalota, Anna, Grace R. Jeschke, Martin Carroll, & Elizabeth O. Hexner. (2013). Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis. Clinical Cancer Research. 19(7). 1729–1739. 13 indexed citations
18.
Porter, David, Elizabeth O. Hexner, Sarah Cooley, & Jeffrey S. Miller. (2008). Cellular Adoptive Immunotherapy After Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. Cancer treatment and research. 144. 497–537. 3 indexed citations
19.
Zhang, Yi, Elizabeth O. Hexner, Dale Frank, & Stephen G. Emerson. (2007). CD4+ T Cells Generated De Novo from Donor Hemopoietic Stem Cells Mediate the Evolution from Acute to Chronic Graft-versus-Host Disease. The Journal of Immunology. 179(5). 3305–3314. 62 indexed citations
20.
Zhang, Yi, Gerard Joe, Elizabeth O. Hexner, Jiang Zhu, & Stephen G. Emerson. (2005). Alloreactive Memory T Cells Are Responsible for the Persistence of Graft-versus-Host Disease. The Journal of Immunology. 174(5). 3051–3058. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pearlie K. Epling‐Burnette Breakdown of academic impact, for papers by Luen Bik To Breakdown of academic impact, for papers by Vincent Praloran Breakdown of academic impact, for papers by Hyeoung‐Joon Kim Breakdown of academic impact, for papers by Simrit Parmar Breakdown of academic impact, for papers by Javier Pinilla‐Ibarz Breakdown of academic impact, for papers by Kazimierz Kuliczkowski Breakdown of academic impact, for papers by David A. Sallman Breakdown of academic impact, for papers by George E. Georges Breakdown of academic impact, for papers by Anna Ritá Migliaccio
Rankless by CCL
2026